-
Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013;26:733-7. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010;30:216-23. -
Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy.
Khalil A, Akolekar R, Pandya P, Syngelaki A, Nicolaides K.
Obstet Gynecol 2010;116:374-80. -
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:680-7. -
Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
Prenat Diagn 2010;30:191-7. -
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH.
Fetal Diagn Ther 2009;25:336-9. -
First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009;53:812-8. -
First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia.
Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:23-33. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Casagrandi D, Skyfta E, Ahmed AA, Nicolaides KH.
Prenat Diagn 2009;29:847-51. -
Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH.
Prenat Diagn 2009;29:753-60. -
Maternal serum activin at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2009;25:320-7. -
Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:622-6.